found that LINC00152 could function as a competing endogenous RNA to modulate the expression of miR‐193a‐3p, and then confer oxaliplatin resistance; LINC00152 may be used as a candidate prognostic indicator of outcome and drug responsiveness in colon cancer 29. Here, CYTOR is linked to malignant colon neoplasm.